Charles River Laboratories International Accounts Receivables 2011-2026 | CRL

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Charles River Laboratories International

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
709 M	721 M	780 M	752 M	643 M	618 M	514 M	472 M	430 M	364 M	270 M	258 M	221 M	203 M	185 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
780 M	185 M	476 M

Quarterly Accounts Receivables Charles River Laboratories International

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
734 M	768 M	757 M	721 M	754 M	762 M	-	780 M	799 M	801 M	788 M	752 M	771 M	-	698 M	643 M	660 M	644 M	611 M	618 M	618 M	618 M	618 M	514 M	514 M	514 M	514 M	472 M	472 M	472 M	472 M	430 M	430 M	430 M	430 M	364 M	364 M	364 M	364 M	270 M	270 M	270 M	270 M	258 M	258 M	258 M	258 M	221 M	221 M	221 M	221 M	203 M	203 M	203 M	203 M	185 M	185 M	185 M	185 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
801 M	185 M	466 M

Accounts Receivables of other stocks in the Diagnostics research industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Agilent Technologies A	1.17 B	$ 110.24	-2.86 %	$ 33.5 B	USA
Waters Corporation WAT	829 M	$ 289.16	-3.79 %	$ 17.2 B	USA
Exagen XGN	10.9 M	$ 2.68	-3.94 %	$ 57.8 M	USA
Enzo Biochem ENZ	3.99 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	299 M	-	-	$ 19.8 B	USA
Akumin AKU	114 M	-	-17.87 %	$ 25.9 M	Canada
Burning Rock Biotech Limited BNR	88.2 M	$ 16.36	-11.57 %	$ 176 M	China
Sotera Health Company SHC	139 M	$ 13.13	-3.03 %	$ 3.73 B	USA
Heska Corporation HSKA	29.5 M	-	-	$ 1.31 B	USA
BioNano Genomics BNGO	5.2 M	$ 1.16	0.87 %	$ 6.32 M	USA
DermTech DMTK	2.58 M	-	-11.32 %	$ 2.94 M	USA
Aspira Women's Health AWH	1.24 M	-	-6.19 %	$ 10.5 M	USA
DexCom DXCM	1.22 B	$ 62.25	-5.81 %	$ 24.3 B	USA
Accelerate Diagnostics AXDX	2.42 M	-	-61.36 %	$ 2.46 M	USA
Global Cord Blood Corporation CO	416 M	-	-	$ 399 M	China
HTG Molecular Diagnostics HTGM	1.42 M	-	-20.0 %	$ 1.06 M	USA
Castle Biosciences CSTL	51.2 M	$ 23.53	-4.74 %	$ 654 M	USA
Quest Diagnostics Incorporated DGX	1.41 B	$ 195.51	-1.33 %	$ 21.7 B	USA
Organovo Holdings ONVO	30 K	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	29.3 K	-	-16.95 %	$ 1.54 M	USA
Biocept BIOC	2.15 M	-	-13.05 %	$ 7.29 M	USA
PerkinElmer PKI	783 M	-	-0.91 %	$ 14.7 B	USA
Invitae Corporation NVTA	96.1 M	-	-	$ 21.2 M	USA
Interpace Biosciences IDXG	8.54 M	$ 1.68	-2.89 %	$ 7.37 M	USA
Motus GI Holdings MOTS	76 K	-	-34.28 %	$ 263 K	Israel
QIAGEN N.V. QGEN	381 M	-	-	$ 10.6 B	Niderland
Neogen Corporation NEOG	153 M	$ 8.7	-4.92 %	$ 1.89 B	USA
Chembio Diagnostics CEMI	6.54 M	-	0.22 %	$ 16.8 M	USA
Laboratory Corporation of America Holdings LH	2.1 B	$ 264.2	-1.56 %	$ 22 B	USA
Psychemedics Corporation PMD	3.69 M	-	-1.84 %	$ 15.3 M	USA
Precipio PRPO	1.3 M	$ 25.97	-4.52 %	$ 33.7 M	USA
CareDx, Inc CDNA	42.6 M	$ 16.78	-3.95 %	$ 894 M	USA
Quotient Limited QTNT	5.32 M	-	-11.32 %	$ 1.1 M	Schweiz
Syneos Health SYNH	729 M	-	-	$ 4.46 B	USA
Renalytix AI plc RNLX	100 K	-	5.66 %	$ 22.7 M	Britain
VolitionRx Limited VNRX	111 K	$ 0.2	1.87 %	$ 19.2 M	Singapore
Bioventus BVS	128 M	$ 8.94	-3.46 %	$ 596 M	USA
Co-Diagnostics CODX	304 K	$ 4.4	101.83 %	$ 129 M	USA
Meridian Bioscience VIVO	47.2 M	-	-	$ 1.49 B	USA
Danaher Corporation DHR	3.91 B	$ 181.52	-3.27 %	$ 129 B	USA
Surmodics SRDX	13.3 M	-	-	$ 608 M	USA
ENDRA Life Sciences NDRA	6.85 K	$ 4.29	-6.54 %	$ 2.3 M	USA